CN113728103B - 治疗精神分裂症和其他神经精神病症的方法 - Google Patents
治疗精神分裂症和其他神经精神病症的方法 Download PDFInfo
- Publication number
- CN113728103B CN113728103B CN201980091600.4A CN201980091600A CN113728103B CN 113728103 B CN113728103 B CN 113728103B CN 201980091600 A CN201980091600 A CN 201980091600A CN 113728103 B CN113728103 B CN 113728103B
- Authority
- CN
- China
- Prior art keywords
- smad4
- glial
- scz
- cells
- entirety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510144182.8A CN119925614A (zh) | 2018-12-11 | 2019-12-11 | 治疗精神分裂症和其他神经精神病症的方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778145P | 2018-12-11 | 2018-12-11 | |
| US62/778,145 | 2018-12-11 | ||
| PCT/US2019/065742 WO2020123663A1 (en) | 2018-12-11 | 2019-12-11 | Methods of treating schizophrenia and other neuropsychiatric disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510144182.8A Division CN119925614A (zh) | 2018-12-11 | 2019-12-11 | 治疗精神分裂症和其他神经精神病症的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113728103A CN113728103A (zh) | 2021-11-30 |
| CN113728103B true CN113728103B (zh) | 2025-02-28 |
Family
ID=69160318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980091600.4A Active CN113728103B (zh) | 2018-12-11 | 2019-12-11 | 治疗精神分裂症和其他神经精神病症的方法 |
| CN202510144182.8A Pending CN119925614A (zh) | 2018-12-11 | 2019-12-11 | 治疗精神分裂症和其他神经精神病症的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510144182.8A Pending CN119925614A (zh) | 2018-12-11 | 2019-12-11 | 治疗精神分裂症和其他神经精神病症的方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220025379A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3894556A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7518547B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113728103B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019396450B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3122289A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020123663A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9709553B2 (en) | 2008-05-08 | 2017-07-18 | University Of Rochester | Treating myelin diseases with optimized cell preparations |
| EP3766962B1 (en) | 2013-02-06 | 2025-10-22 | University of Rochester | Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders |
| US9724432B2 (en) | 2015-04-30 | 2017-08-08 | University Of Rochester | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder |
| EP3621434B1 (en) | 2017-05-10 | 2026-07-15 | University of Rochester | Glial progenitor cells for use in treating schizophrenia |
| US12303549B2 (en) | 2018-06-21 | 2025-05-20 | University Of Rochester | Methods of treating or inhibiting onset of Huntington's disease |
| CN118924886A (zh) * | 2023-03-16 | 2024-11-12 | 郑州大学 | 肿瘤共享新抗原表位肽或其编码核酸的新用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080119427A1 (en) | 1996-06-06 | 2008-05-22 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6838283B2 (en) | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
| BRPI0008131B8 (pt) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
| US6013787A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense modulation of Smad4 expression |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| US7179796B2 (en) | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| EP1857547B2 (en) | 2002-08-05 | 2020-12-02 | Silence Therapeutics GmbH | Further novel forms of interfering RNA molecules |
| EP2182063A3 (en) | 2003-09-18 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Modulation of EIF4E expression |
| US7128264B2 (en) | 2004-07-23 | 2006-10-31 | Symbol Technologies, Inc: | Electro-optical reader with improved performance in high intensity ambient light |
| JP4428296B2 (ja) | 2005-06-10 | 2010-03-10 | セイコーエプソン株式会社 | 表示パネルモジュールおよび表示装置 |
| US9962558B2 (en) * | 2005-08-05 | 2018-05-08 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
| EP2206724A1 (en) | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
| DK3399025T3 (da) | 2007-03-23 | 2025-06-16 | Wisconsin Alumni Res Found | Omprogrammering af somatiske celler |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| EP2315829B1 (en) | 2008-08-08 | 2015-02-11 | Mayo Foundation For Medical Education And Research | Induced pluripotent stem cells |
| WO2011062963A2 (en) | 2009-11-17 | 2011-05-26 | Vitro Diagnositics, Inc. | Induced puripotent stem cells and related methods |
| US9005967B2 (en) | 2010-01-22 | 2015-04-14 | Kyoto University | Myc variants improve induced pluripotent stem cell generation efficiency |
| EP2723861A4 (en) * | 2011-06-21 | 2014-12-10 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION |
| AU2012332269B2 (en) * | 2011-11-04 | 2018-05-31 | Memorial Sloan-Kettering Cancer Center | Midbrain dopamine (DA) neurons for engraftment |
| US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
| US20180263226A1 (en) | 2015-01-16 | 2018-09-20 | The Board Of Regents Of The University Of Texas System | Compositions and methods for creating pancreatic cancer animal model |
-
2019
- 2019-12-11 AU AU2019396450A patent/AU2019396450B2/en active Active
- 2019-12-11 CN CN201980091600.4A patent/CN113728103B/zh active Active
- 2019-12-11 CA CA3122289A patent/CA3122289A1/en active Pending
- 2019-12-11 EP EP19836294.9A patent/EP3894556A1/en active Pending
- 2019-12-11 WO PCT/US2019/065742 patent/WO2020123663A1/en not_active Ceased
- 2019-12-11 US US17/413,384 patent/US20220025379A1/en active Pending
- 2019-12-11 JP JP2021533154A patent/JP7518547B2/ja active Active
- 2019-12-11 CN CN202510144182.8A patent/CN119925614A/zh active Pending
-
2024
- 2024-06-28 JP JP2024104638A patent/JP2024129091A/ja active Pending
Non-Patent Citations (9)
| Title |
|---|
| Antiepileptic Drugs Elevate Astrocytic Kir4.1 Expression in the Rat Limbic Region;Takahiro Mukai等;Frontiers in Pharmacology;第9卷;Article 845,第1-9页 * |
| Dysregulated Glial Differentiation in Schizophrenia May Be Relieved by Suppression of SMAD4- and REST-Dependent Signaling;Zhengshan Liu等;Cell Reports;20190625;第27卷;3832–3843 * |
| HDAC2-dependent antipsychotic-like effects of chronic treatment with the HDAC inhibitor SAHA in mice;Mario de la Fuente Revenga等;Neuroscience;第388卷;102–117 * |
| Ping-Tao Tseng等.Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia.Medicine.2016,第95卷(第4期),1-10. * |
| Po-Sheng Wang等.The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia.International Clinical Psychopharmacology.2014,第29卷(第4期),235-238. * |
| Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia;Ping-Tao Tseng等;Medicine;第95卷(第4期);1-10 * |
| Takahiro Mukai等.Antiepileptic Drugs Elevate Astrocytic Kir4.1 Expression in the Rat Limbic Region.Frontiers in Pharmacology.2018,第9卷Article 845,第1-9页. * |
| The Contribution of Glial Molecular Pathology to Schizophrenia;Zhengshan Liu;UR RESEARCH;第1-137页 * |
| The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia;Po-Sheng Wang等;International Clinical Psychopharmacology;第29卷(第4期);235-238 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3122289A1 (en) | 2020-06-18 |
| CN113728103A (zh) | 2021-11-30 |
| JP7518547B2 (ja) | 2024-07-18 |
| US20220025379A1 (en) | 2022-01-27 |
| JP2024129091A (ja) | 2024-09-26 |
| WO2020123663A1 (en) | 2020-06-18 |
| JP2022511568A (ja) | 2022-01-31 |
| EP3894556A1 (en) | 2021-10-20 |
| CN119925614A (zh) | 2025-05-06 |
| AU2019396450A1 (en) | 2021-06-24 |
| AU2019396450B2 (en) | 2025-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7518547B2 (ja) | 統合失調症及び他の神経精神障害の治療方法 | |
| KR20190051020A (ko) | 안 질환 치료용 안티센스 올리고뉴클레오타이드 | |
| JP2021520200A (ja) | 非神経細胞のニューロンへの再プログラミング、及び神経変性疾患または障害を治療するための方法と組成物 | |
| JP2024075673A (ja) | 統合失調症及び他の神経精神障害の治療方法 | |
| CN120022289A (zh) | 血管生成素样7(angptl7)相关疾病的治疗 | |
| KR20260013449A (ko) | Mapt를 조절하기 위한 조성물 및 방법 | |
| JP7786750B2 (ja) | Tcf4遺伝子発現を調節するため、およびピット・ホプキンス症候群を治療するための組成物および方法 | |
| WO2021156831A1 (en) | Mirna-485 inhibitor for gene upregulation | |
| US20220186228A1 (en) | Synthetic microrna mimics | |
| US20260022377A1 (en) | Polynucleotide compositions and methods for treatment of neurodegenerative diseases | |
| WO2025049527A1 (en) | Y-rna compositions and methods of using the same | |
| HK40130645A (en) | Polynucleotide compositions and methods for treatment of neurodegenerative diseases | |
| EP4599061A1 (en) | Antisense oligonucleotides for treatment of usher 2a. exon 68 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |